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Background: Augmentation of Ca2+ entry via transient receptor
potential canonical channel 6 (TRPC6) in response to stimulation of
endothelin type A receptor (ETAR) with endothelin-1 is involved in the
development of pulmonary arterial hypertension (PAH). For the drug
therapy against PAH, Gs protein-coupled prostaglandin I2 receptor
agonists to activate adenylate cyclase (AC)-cAMP-protein kinase A
(PKA) signaling pathway are administered. This study examined the
role of AC-cAMP-PKApathway in regulation of receptor-operated Ca2+
entry (ROCE) via ETAR-activated TRPC6.
Methods: In HEK293 cells coexpressing ETAR and TRPC6, intracel-
lular free Ca2+ concentration was monitored by using a ﬂuorescent
Ca2+ indicator, fura-2/AM. To identify the target site(s) of TRPC6 for
phosphorylation by PKA, serine residues at positions 14, 28, and 321,
and threonine at 69 were replaced with alanine.
Results: Stimulation of ETAR induced ROCE in TRPC6-expressing
HEK293 cells where store-operated Ca2+ channels had been maxi-
mally activated by thapsigargin-induced Ca2+-depletion/Ca2+-
restoration. The ROCE was inhibited by forskolin and papaverine to
activate cAMP-PKA pathway, while it was potentiated by Rp-8-Br-
cAMP, a PKA inhibitor. Inhibitory effects of forskolin and papaverine
were partially cancelled by replacing Ser28 but not Thr69 of TRPC6
with alanine. Immunoblotting with Phos-tag biotin to detect
phosphorylated proteins demonstrated that wild-type and mutant
TRPC6 proteins were phosphorylated under basal condition. In vitro
kinase assay with TRPC6 proteins dephosphorylated with a phos-
phatase pretreatment revealed that PKA can phosphorylate TRPC6 on
Ser28 and Thr69.
Conclusions: ROCE via ETAR-activated TRPC6 is negatively regulated
by PKA-mediated phosphorylation of TRPC6 at Ser28 but not at Thr69 in
vivo, although PKA can phosphorylate TRPC6 on Ser28 and Thr69 in
vitro.
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A growing body of evidence suggests that microRNAs (miRNAs)
regulate endothelin-1 (Edn1) mRNA bioavailability (Jacobs et.
al.,2013). miRNAs are a family of small (18–24 nt), single stranded,
noncoding RNAs that are components of the RNA-induced Silencing
Complex (RISC). RISC controls gene expression by blocking protein
translation or inducing degradation of target mRNAs by binding to
the 3′ untranslated region (UTR). In humans and other mammals, the
Edn1 3′ UTR represents over 50% of the total mRNA length and
contains long tracts of highly conserved sequence. Alignment of 19
species of class Mammalia yielded greater than 80% sequence
identity between any two Edn1 3′UTRs. The level of conservation
by itself suggests that there are elements in the 3′ UTR that are
critical for tight regulation of Edn1 mRNA availability. In silico
examination of the murine Edn1 3′ UTR revealed two likely miR-709
binding sites at positions 610 and 668 (microRNA.org). mFold
(http://mfold.rna.albany.edu) was used to examine the free energy
of 70 nucleotides ﬂanking the putative miRNA binding sites in the
Edn1 3′UTR. The minimum free energy values were higher than
randomly expected (delta G =−13.4 kcal/mol) (Martin et al., 2007),
suggesting that these sites are accessible to miRNA-RISC complexes.
Inhibiting miR-709 through the use of anti-miRNA inhibitors
demonstrated that miR-709 signiﬁcantly affected Edn1 mRNA levels.
Immunoprecipitation of the RISC subunit Argonaute demonstrated a
direct interaction between RISC and Edn1 mRNA. The transfection of
anti-miR-709 inhibitors prior to the RISC immunoprecipitation
blocked RISC-Edn1 mRNA interaction. Aldosterone treatment of cells
dramatically changed the amount of Edn1 mRNA targeted by RISC.
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We have discovered that ET-1 mediated constrictor responses in
human coronary artery (CA) in vitro are not attenuated in
atherosclerotic compared to histologically normal arteries, despite
extensive thinning of the medial smooth muscle layer with disease.
This observation can be replicated in the aorta of mice in which 50%
of smooth muscle cells are ablated without subsequent loss of ET-1
response. To further understand these data we have investigated the
effect of altered arterial structure (medial thinning, intimal prolifer-
ation and calcium/lipid deposition) on the passive mechanical
properties of the vessel wall and determined whether this may
contribute to the maintained ET-1 response in diseased CA. Passive
force-stretch tests were performed to characterize the artery
mechanical response and tangent stiffness at physiological pressure
of normal and diseased CA rings. Results demonstrated that
differences in material and geometry lead to a signiﬁcant increase
in the passive response with disease. However when these structural
differences were included in a ﬁnite element analysis to predict the
effect of plaque morphology, material properties and muscle
contractile strain on both the passive and ET-mediated active
responses, it was found that the comparable ET-1 responses could
only be explained by assigning similar active forces in both the
normal and diseased CA rings. This study has identiﬁed an
appropriate methodology to correlate pharmacological and bio-
mechanical models of stress and strain in arteries. However,
although the atherosclerotic CA wall exhibits structural remodeling
resulting in arterial stiffening this does not account for the ability of
the diseased arteries to contract to ET-1 to the same extent as normal
arteries.
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